Elsevier

Annals of Oncology

Volume 27, Supplement 6, 1 October 2016, Page vi170
Annals of Oncology

Submitted abstracts
Gastrointestinal tumours, colorectal
516P - Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial

https://doi.org/10.1093/annonc/mdw370.64Get rights and content
Under an Elsevier user license
open archive

Cited by (0)